Nechifor-Boila et al. suggest that BRAF V600E in PTC acts synergistically with aggressive pathological features such as extrathyroidal extension pT3b tumor stage, lymph node metastasis, positive surgical resection margins, persistent disease status and distant metastases [36]. Here, BRAF is linked to metastatic malignant neoplasm in the lymph nodes.